The results consistently demonstrated that NAT10 expression in breast cancer tissues positively correlated with CD2BP2‐DT and CDK1 levels, suggesting that NAT10 acts as an upstream regulator of the CD2BP2‐DT/CDK1 signaling axis (Figure 8C–E; Figure S8B, Supporting Information). Here, NAT10 is linked to breast carcinoma.